71 related articles for article (PubMed ID: 21790722)
1. Peroxisome proliferator activated receptor-α agonists suppress transforming growth factor-α-induced matrix metalloproteinase-9 expression in human keratinocytes.
Meissner M; Berlinski B; Gille J; Doll M; Kaufmann R
Clin Exp Dermatol; 2011 Dec; 36(8):911-4. PubMed ID: 21790722
[TBL] [Abstract][Full Text] [Related]
2. AP1-dependent repression of TGFα-mediated MMP9 upregulation by PPARδ agonists in keratinocytes.
Meissner M; Berlinski B; Doll M; Hrgovic I; Laubach V; Reichenbach G; Kippenberger S; Gille J; Kaufmann R
Exp Dermatol; 2011 May; 20(5):425-9. PubMed ID: 21496113
[TBL] [Abstract][Full Text] [Related]
3. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1.
Ala-aho R; Johansson N; Grénman R; Fusenig NE; López-Otín C; Kähäri VM
Oncogene; 2000 Jan; 19(2):248-57. PubMed ID: 10645003
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Grau R; Punzón C; Fresno M; Iñiguez MA
Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator--activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes.
Fahmi H; Di Battista JA; Pelletier JP; Mineau F; Ranger P; Martel-Pelletier J
Arthritis Rheum; 2001 Mar; 44(3):595-607. PubMed ID: 11263774
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages.
Souissi IJ; Billiet L; Cuaz-Pérolin C; Slimane MN; Rouis M
Exp Cell Res; 2008 Nov; 314(18):3405-14. PubMed ID: 18823978
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor α and γ agonists together with TGF-β convert human CD4+CD25- T cells into functional Foxp3+ regulatory T cells.
Lei J; Hasegawa H; Matsumoto T; Yasukawa M
J Immunol; 2010 Dec; 185(12):7186-98. PubMed ID: 21057085
[TBL] [Abstract][Full Text] [Related]
9. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes.
Hua Y; Xue J; Sun F; Zhu L; Xie M
Pharmacology; 2009; 83(1):18-25. PubMed ID: 18971601
[TBL] [Abstract][Full Text] [Related]
10. Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.
Cho MC; Lee S; Choi HS; Yang Y; Tae Hong J; Kim SJ; Yoon DY
Immunopharmacol Immunotoxicol; 2009; 31(3):459-67. PubMed ID: 19263263
[TBL] [Abstract][Full Text] [Related]
11. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
François M; Richette P; Tsagris L; Fitting C; Lemay C; Benallaoua M; Tahiri K; Corvol MT
Arthritis Rheum; 2006 Apr; 54(4):1233-45. PubMed ID: 16572457
[TBL] [Abstract][Full Text] [Related]
12. The effects of Musk T on peroxisome proliferator-activated receptor [PPAR]-alpha activation, epidermal skin homeostasis and dermal hyaluronic acid synthesis.
Kim SH; Nam GW; Lee HK; Moon SJ; Chang IS
Arch Dermatol Res; 2006 Nov; 298(6):273-82. PubMed ID: 16977445
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha-stimulated membrane type 1-matrix metalloproteinase production is modulated by epidermal growth factor receptor signaling in human gingival fibroblasts.
Smith PC; Guerrero J; Tobar N; Cáceres M; González MJ; Martínez J
J Periodontal Res; 2009 Feb; 44(1):73-80. PubMed ID: 19515020
[TBL] [Abstract][Full Text] [Related]
15. Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta.
Johansson N; Westermarck J; Leppä S; Häkkinen L; Koivisto L; López-Otín C; Peltonen J; Heino J; Kähäri VM
Cell Growth Differ; 1997 Feb; 8(2):243-50. PubMed ID: 9040946
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase.
Xiao X; Su G; Brown SN; Chen L; Ren J; Zhao P
J Nutr Biochem; 2010 Jul; 21(7):621-6. PubMed ID: 19570670
[TBL] [Abstract][Full Text] [Related]
17. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells.
Jung Y; Kim JC; Choi Y; Lee S; Kang KS; Kim YK; Kim SN
Biochem Biophys Res Commun; 2017 Nov; 493(1):220-226. PubMed ID: 28899779
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
[TBL] [Abstract][Full Text] [Related]
19. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse.
Delayre-Orthez C; Becker J; Guenon I; Lagente V; Auwerx J; Frossard N; Pons F
Respir Res; 2005 Aug; 6(1):91. PubMed ID: 16091136
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Nakamachi T; Nomiyama T; Gizard F; Heywood EB; Jones KL; Zhao Y; Fuentes L; Takebayashi K; Aso Y; Staels B; Inukai T; Bruemmer D
Diabetes; 2007 Jun; 56(6):1662-70. PubMed ID: 17360982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
